BloombergBiogen Idec Q2 profits rise on strong Avonex salesPMLiVEEnrolment has been completed in the DECIDE trial of another MS drug candidate, daclizumab, with results expected in 2014, said Williams, while a phase IIa trial has got underway for STX-1…
Biogen Idec 2nd-qtr sales and earnings top analysts expectationsThe Pharma Letter… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase III A-LONG and B-LONG trials for…
Biogen Idec sees revenue surge on MS drug salesMedical Marketing and MediaThe firm has seven products in Phase II clinical trials, including treatments for Hemophilia A and B, Amyotrophic Lateral Sclerosis, Chroic Lymphocitic Leukemia and Non-Hodgkin&#…
BloombergBiogen Idec Management Discusses Q2 2012 Results – Earnings Call TranscriptSeeking AlphaMoving on to daclizumab. We completed enrollment in this side, the second registrational trial for daclizumab and relapsing-remitting MS with more than 180…
Biogen Idec-Aktie: Gewinn im zweiten Quartal legt zuboerse.de (Pressemitteilung)21.09.10, Biogen Idec mögliche Konkurrenz für Multiple Sklerose-Franchise. 16.09.10, Biogen Idec "equal weight". 29.10.10, Biogen Idec Downgrade. 24.05.10, Biog…
Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second QuarterPharmaLive (press release) (subscription)… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3…
CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 …MarketWatch (press release)… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3 A-LONG and B-L…
Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second QuarterMarketWatch (press release)… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3 A-LONG and B-…
SEP : un risque de rechute majoré après arrêt du natalizumabMedscape France[Medscape France > Actualités ; 4 mai 2012]; Surveillance cardiovasculaire renforcée pour un traitement de la SEP [Medscape France > Actualités ; 2 mai 2012]; Le dac…
Sclerosi Multipla: uno studio canadese smentisce l'efficacia dell'interferone beta …informazione.it (Comunicati Stampa)Biogen Idec e Abbott annunciano i risultati positivi della prima sperimentazione per la registrazione di Daclizumab HYP nel…